Table 1.
Demographic and clinical characteristics at baseline in the ITT population
| Placebo (N=122) | Rupatadine 10 mg (N=117) | Desloratadine 5 mg (N=117) | P-value (ANOVA) | |
|---|---|---|---|---|
| Sex (male) [N (%)] | 66 (54.1) | 61 (52.1) | 52 (44.4) | NS* |
| Age (years) [mean (SD)] | 31.8 (12.6) | 30.8 (11.2) | 32 (12.5) | NS |
| Race (Caucasian) [N (%)] | 121 (99.2) | 114 (99.1) | 114 (99.1) | NS** |
| Weight (kg) [mean (SD)] | 71.4 (16.8) | 69.4 (12.8) | 68.1 (15.2) | NS |
| BMI (kg/m2) [mean (SD)] | 24.1 (4.4) | 23.9 (3.6) | 23.5 (4.01) | NS |
| T7SS [mean (SD)] | ||||
| Reflective | 14.01 (2.77) | 13.77 (2.68) | 13.68 (2.67) | NS |
| Instantaneous | 12.86 (3.69) | 12.93 (3.51) | 12.65 (3.60) | NS |
| T4NSS [mean (SD)] | ||||
| Reflective | 8.66 (1.51) | 8.52 (1.52) | 8.58 (1.53) | NS |
| Instantaneous | 7.90 (2.18) | 8.03 (2.06) | 7.93 (2.09) | NS |
| T3NNSS [mean (SD)] | ||||
| Reflective | 5.35 (1.56) | 5.25 (1.48) | 5.10 (1.51) | NS |
| Instantaneous | 4.96 (1.82) | 4.89 (1.75) | 4.73 (1.83) | NS |
Notes: *P-value obtained with the Chi-square test; **P-value obtained with Fisher’s exact test.
Abbreviations: ITT, intention to treat; N, number; ANOVA, analysis of variance; NS, not significant; SD, standard deviation; BMI, body mass index; T7SS, total seven symptoms score; T4NSS, total four symptoms score; T3NNSS, total three nonnasal symptoms score.